GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
Is a Surprise in the Cards for Novartis in Q2 Earnings?
by Zacks Equity Research
Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.
Pfizer (PFE) to Reorganize Business Into Three New Units
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
by Zacks Equity Research
The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
PFE vs. GSK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. GSK: Which Stock Is the Better Value Option?
Novartis to Spin-Off Alcon as Separate Trading Company
by Zacks Equity Research
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
New Strong Sell Stocks for July 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
by Kinjel Shah
In the first six months of the year, the FDA grants approval to 17 new treatments.
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
by Zacks Equity Research
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
Will a Trade War With China Wreak Havoc in US Healthcare?
by Nitish Marwah
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel
by Zacks Equity Research
Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.
Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
by Zacks Equity Research
Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.
Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection
by Zacks Equity Research
Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
by Zacks Equity Research
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
by Zacks Equity Research
Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis
Large Cap Pharma Stock Outlook: Short-Term Struggle Likely
by Zacks Equity Research
Drug pricing scrutiny, pricing and competitive pressure, and major pipeline setbacks can hurt the performance of the large-cap pharmaceuticals sector in the short term.
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
by Zacks Equity Research
Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen
Company News For Jun 15, 2018
by Zacks Equity Research
Companies In The News are: ETSY,RCL,MYL,GSK,TWTR
Mylan (MYL) to Get CRL Again for Generic Advair from FDA
by Zacks Equity Research
Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.
Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works
Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.
Top Stock Reports for Chevron, Glaxo & T-Mobile
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Glaxo (GSK) and T-Mobile (TMUS).
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
Merck Presents Positive Melanoma Data on Keytruda at ASCO
by Zacks Equity Research
Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.